A Novel Phthalimide Derivative, TC11, Has Preclinical Effects on High-Risk Myeloma Cells and Osteoclasts

• Maiko Matsushita,

  Affiliation Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo, Japan

  ⨯
• Yoshie Ozaki,

  Affiliation Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo, Japan

  ⨯
• Yuka Hasegawa,

  Affiliation Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo, Japan

  ⨯
• Fukiko Terada,

  Affiliation Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo, Japan

  ⨯
• Noriko Tabata,

  Affiliation Department of Biosciences and Informatics, Faculty of Science and Technology, Keio University, Yokohama, Japan

  ⨯
• Hirokazu Shiheido,

  Affiliation Department of Biosciences and Informatics, Faculty of Science and Technology, Keio University, Yokohama, Japan

  ⨯
• Hiroshi Yanagawa,

  Affiliation Department of Biosciences and Informatics, Faculty of Science and Technology, Keio University, Yokohama, Japan

  ⨯
• Tsukasa Oikawa,

  Affiliation Cell and Tissue Biology, School of Medicine, Keio University, Tokyo, Japan

  ⨯
• Koichi Matsuo,

  Affiliation Cell and Tissue Biology, School of Medicine, Keio University, Tokyo, Japan

  ⨯
• Wenlin Du,

  Affiliation Department of Pathology, School of Medicine, Keio University, Tokyo, Japan

  ⨯
• Taketo Yamada,

  Affiliation Department of Pathology, School of Medicine, Keio University, Tokyo, Japan

  ⨯
• Masashi Hozumi,

  Affiliation Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo, Japan

  ⨯
• Daiju Ichikawa,

  Affiliation Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo, Japan

  ⨯
• Yutaka Hattori

  * E-mail: hattori-yt@pha.keio.ac.jp

  Affiliation Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo, Japan

  ⨯